Ono Pharmaceutical Co Ltd (4528.T)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|58||2008||President, Representative Director|
|56||2015||Executive Vice President, Chief Director of Development, Director|
|58||2017||Senior Managing Executive Officer, Chief Director of Business Administration, Director of Product Strategy, Director|
|55||2017||Managing Executive Officer, Chief Director of Sales|
|57||2016||Managing Executive Officer, Chief Director of Reliability Assurance, Director|
- BRIEF-Ono Pharmaceutical enters into license agreement with Bristol-Myers Squibb for Prostaglandin E2 receptor antagonists
- BRIEF-Bristol-Myers Squibb Granted Exclusive License By Ono Pharmaceutical For Multiple Programs Targeting Immuno-Suppressive Factors In The Tumor Microenvironment
- BRIEF-Ono Pharmaceutical completes retirement of treasury shares
- BRIEF-Karyopharm and Ono Pharmaceutical sign exclusive license agreement to develop and commercialize Selinexor and KPT-8602 in Japan and other countries in Asia
- Nobel Prize speculation spices up Japan's stock markets